Innovations in the Management of Hepatocellular Carcinoma

No abstract is available for this paper.

• Publication year

  2018

• Venue

  American Journal of Therapeutics

• Publication date

  2018-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/MJT.0000000000000713PMID 29561268
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.

  2017cited by this paper
• SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma.

  2015cited by this paper
• Immunological landscape and immunotherapy of hepatocellular carcinoma

  2015cited by this paper
• Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial.

  2015cited by this paper
• The “Macro” World of microRNAs in Hepatocellular Carcinoma

  2015cited by this paper
• Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial.

  2014cited by this paper
• Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study.

  2013cited by this paper
• Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study.

  2013cited by this paper
• Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial.

  2013cited by this paper
• Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.

  2013cited by this paper
• Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study.

  2013cited by this paper
• Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory disease

  2012cited by this paper
• Early clinical development of ARQ 197, a selective, non-ATP-competitive inhibitor targeting MET tyrosine kinase for the treatment of advanced cancers.

  2011cited by this paper
• Hepatocellular carcinoma.

  2011cited by this paper
• Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity

  2011cited by this paper
• Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial.

  2010cited by this paper
• Development of Molecularly Targeted Therapies in Hepatocellular Carcinoma: Where Do We Go Now?

  2010cited by this paper
• Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study

  2010cited by this paper
• A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients

  2010cited by this paper
• Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer

  2010cited by this paper
• Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy.

  2010cited by this paper
• Targeting c-Myc as a novel approach for hepatocellular carcinoma.

  2010cited by this paper
• Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005.

  2009cited by this paper
• Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model.

  2009cited by this paper
• Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.

  2009cited by this paper
• Cancer Statistics, 2008

  2008cited by this paper
• Sorafenib in advanced hepatocellular carcinoma.

  2008cited by this paper
• Systemic therapy of hepatocellular carcinoma: Are we making progress?

  2008cited by this paper
• Molecular targeted therapies in hepatocellular carcinoma

  2008cited by this paper
• Pivotal role of mTOR signaling in hepatocellular carcinoma.

  2008cited by this paper
• Targeted inhibition of the extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) in the treatment of hepatocellular carcinoma

  2007cited by this paper
• Discovery and development of sorafenib: a multikinase inhibitor for treating cancer

  2007cited by this paper
• The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide.

  2006cited by this paper
• Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.

  2006cited by this paper
• Blockade of IGF-1 receptor tyrosine kinase has antineoplastic effects in hepatocellular carcinoma cells.

  2006cited by this paper
• Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer.

  2005cited by this paper
• Incidence and distribution of argininosuccinate synthetase deficiency in human cancers

  2004cited by this paper
• The IGF axis and hepatocarcinogenesis

  2001cited by this paper
• Association between aflatoxin content of food and hepatoma frequency in Uganda

  1971cited by this paper

• CXCL17 promotes cell metastasis and inhibits autophagy via the LKB1-AMPK pathway in hepatocellular carcinoma.

  2019cites this paper